Immunosuppressive drugs and pregnancy: Mycophenolate mofetil embryopathy

NeoReviews

Volumn 11, Issue 10, 2010, Pages

  Perez Aytes, A ^a   Ledo, Ana ^a   Boso, Virginia ^a   Carey, John C ^b   Castell, Marta ^a   Vento, Maximo ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78049264941     PISSN: None     EISSN: 15269906     Source Type: Journal    
DOI: 10.1542/neo.11-10-e578     Document Type: Article

References (60)

1. McKay DB, Josephson MA. Pregnancy in recipients of solid organs. Effects on mother and child. N Engl J Med. 2006;354: 1281-1293
2. Armenti VT, Constantinescu S, Moritz MJ, Davison JM. Pregnancy after transplantation. Transplant Rev. 2008;22:223-240
3. Matesanz R. El transplante de órganos sólidos en España: éxito de una política. Rev Clin Esp. 2000;200:157-162
4. Sivaraman P. Management of pregnancy in transplant recipients. Transplant Proc. 2004;36:1999-2000
5. Armenti VT, Radomski JS, Moritz MJ, et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transplant. 2004;103-114
6. Kainz A, Harabacz I, Cowlrick IS, Gadgil SD, Hagiwara D. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation. 2000;70:1718-1721
7. Fuchs KM, Coustan DR. Immunosuppressive therapy in pregnant organotransplant recipients. Semin Perinatol. 2007;31: 363-371
8. Ingle GR, Shah T. Enteric-coated mycophenolate sodium for transplant immunosuppression. Am J Health Syst Pharm. 2005;62: 2252-2259
9. Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus 2005;14(suppl 1):S2-S8
10. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46:13-58
11. Shaw LM, Figurski M, Milone MC, Trofe J, Bloom RD. Therapeutic drug monitoring of mycophenolic acid. Clin J Am Soc Nephrol. 2007;5:1062-1072
12. Hesselink DA, van Gelder T. Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. Clin Pharmacol Ther. 2005;78:317-321
13. Cattaneo D, Baldelli S, Perico N. Pharmacogenetics of immunosuppressants: progress, pitfalls and promises. Am J Transplant. 2008;8:1374-1383
14. Dalal P, Grafals M, Chhabra D, Gallon L. Mycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection. Ther Clin Risk Manag. 2009;5:139-149
15. Sollinger HW. From mice to man: the preclinical history of mycophenolate mofetil. Clin Transplant. 1996;10:85-92
16. Sollinger HW, Deierhoi MH, Belzer FO, Diethelm AG, Kauffman RS. RS-61443-a phase I clinical trial and pilot rescue study. Transplantation. 1992;53:428-432
17. Sinclair A, Baildon R. Mycophenolate mofetil: an overview. Lupus. 2006;15:70-78
18. Sollinger HW. Mycophenolates in transplantation. Clin Transplant. 2004;18:485-492
19. Golshayan D, Pascual M, Vogt B. Mycophenolic acid formulation in adult renal transplantation - update on efficacy and tolerability. Ther Clin Risk Manag. 2009;5:341-351
20. Bandelier C, Guerne PA, Genevay S, Finckh A, Gabay C. Clinical experience with mycophenolate mofetil in systemic autoimmune conditions refractory to common immunosuppressive therapies. Swiss Med Wkly. 2009;139:41-46
21. Ulinsky T, Dubourg L, Saïd MH, Parchoux B, Ranchin B, Cochat P. Switch from cyclosporine A to mycophenolate mofetil in nephrotic children. Pediatr Nephrol. 2005;20:482-485
22. Mak A, Cheak AA, Tan JY, Su HC, Ho RC, Lau CS. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a metaanalysis and meta-regression. Rheumatology. 2009;48:944-952
23. Segal T, Webb E, Viner R, Pusey C, Wild G, Allgrove J. Severe insulin resistance secondary to insulin antibodies: successful treatment with the immunosuppressant MMF. Pediatr Diabetes. 2008; 9:250-254
24. Mielli-Vergani G, Heller S, Jara P, et al. Autoimmune hepatitis. J Pediatr Gastroenterol Nutr. 2009;49:158-164
25. Benatar M, Rowland LP. The muddle of mycophenolate mofetil in myasthenia. Neurology. 2008;71:390-391
26. Tullus K, Marks SD. Vasculitis in children and adolescents: clinical presentation, etiopathogenesis, and treatment. Pediatr Drugs. 2009;11:375-380
27. Salzmann J, Lightman S. The potential of newer immunomodulating drugs in the treatment of uveitis: a review. Bio Drugs. 2000;13:397-408
28. Rallis E, Anyfantakis V. Coexistent psoriasis and bullous pemphigoid responding to mycophenolate mofetil monotherapy. Skinmed. 2008;7:101-102
29. Orvis AK, Wesson SK, Breza TS Jr, Church AA, Mitchell CL, Watkins SW. Mycophenolate mofetil in dermatology. J Am Acad Dermatol. 2009;60:183-199
30. Ricci G, Dondi A, Patrizi A, Masi M. Systemic therapy of atopic dermatitis in children. Drugs. 2009;69:297-306
31. Hashimoto T. Treatment strategies for pemphigus vulgaris in Japan. Expert Opin Pharmacother. 2008;9:1519-30
32. Zhou Y, Rosenthal D, Dutz J, Ho V. Mycophenolate mofetil (Cell Cept) for psoriasis: a two-center, prospective, open-label clinical trial. J Cutan Med Surg. 2003;7:193-197
33. Pérgola PE, Kancharla A, Riley DJ. Kidney transplantation during the first trimester of pregnancy: immunosuppression with mycophenolate mofetil, tacrolimus, and prednisone. Transplantation. 2001;71:994-997
34. Le Ray C, Coulomb A, Elefant E, Frydman R, Audibert F. Mycophenolate mofetil in pregnancy after renal transplantation: a case of major fetal malformations. Obstet Gynecol. 2004;103: 1091-1094
35. Sifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz MJ, Armenti VT. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation. 2006;82:1698-1702
36. Tjeertes IFA, Bastiaans DET, van Ganzewinkel CJML, Zegers SHJ. Neonatal anemia and hydrops fetalis after maternal mycophenolate mofetil use. J Perinatol. 2007;27:62-64
37. El Seebaly Z, Charpentier B, Snanoudj R. Fetal malformations associated with mycophenolate mofetil for lupus nephritis. Nephrol Dial Transplant. 2007;22:2722-2732
38. Perez-Aytes A, Ledo A, Boso V, et al. In utero exposure to mycophenolate mofetil: a characteristic phenotype? Am J Med Genet. 2008;146A:1-7
39. Carey JC, Martinez L, Balken E, Leen-Mitchell M, Robertson J. Determination of human teratogenicity by the astute clinician method: review of illustrative agents and a proposal of guidelines. Birth Defects Res (A) Clin Mol Teratol. 2009;85:63-68
40. Velinov M, Zellers N. The fetal mycophenolate mofetil syndrome. Clin Dysmorphol. 2008;17:77-78
41. Schoner K, Steinhard J, Figiel J, Rehder H. Severe facial clefts in acrofacial dysostosis. A consequence of prenatal mycophenolate mofetil? Obstet Gynecol. 2008;111:483-486
42. Andrade-Vila JH, Da Silva JP, Guilhen CJ, Baumgratz JF, Da Fonseca L. Even low dose of mycophenolate mofetil in a mother recipient of heart transplant can seriously damage the fetus. Transplantation. 2008;86:369-370
43. Ang GS, Simpson SA, Reddy AR. Mycophenolate mofetil embryopathy may be dose and timing dependent. Am J Med Genet. 2008;146A:1963-1966
44. Huang S-Y, Chueh HY, Shaw SW, Shih JC, Cheng PJ. Sonographic diagnosis of fetal malformations associated with mycophenolate mofetil exposure in utero. Am J Obstet Gynecol. 2008;199: e6-e8
45. Anderka MT, Lin AE, Abuelo DN, Mitchell AA, Rasmussen SA. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genet. 2009;149A:1241-1248
46. Jackson P, Paquette L, Watiker V, Randolph L, Ramanathan R, Seri I. Intrauterine exposure to mycophenolate mofetil and multiple congenital anomalies in a newborn infant: possible teratogenic effect. Am J Med Genet. 2009;149A:1231-1236
47. Parisi MA, Zayed H, Slavotinek AM, Rutledge JC. Congenital diaphragmatic hernia and microtia in a newborn with mycophenolate mofetil (MMF) exposure: phenocopy for Fryns syndrome or broad spectrum of teratogenic effects? Am J Med Genet. 2009; 149A:1237-1240
48. Verloes A. Updated diagnostic criteria for CHARGE syndrome: a proposal. Am J Med Genet. 2005;133A:306-308
49. Sanlaville D, Verloes A. CHARGE syndrome: an update. Eur J Hum Genet. 2007;15:389-399
50. th ed. Philadelphia, Pa: Elsevier Saunders; 2006:738-739
51. Källén B, Robert E, Castilla EE, Mastroiacovo P, Källén B. Relation between oculo-auriculo-vertebral (OAV) dysplasia and three non-random associations of malformations (VATER, CHARGE, and OEIS). Am J Med Genet. 2004;127A:26-34
52. Kumar A, Friedman M, Taylor GP, Patterson MW. Pattern of cardiac malformation in oculoauriculovertebral spectrum. Am J Med Genet. 1993;46:423-426
53. McDonald MT, Gorski JL. Syndrome of the month: Nager acrofacial dysostosis. J Med Genet. 1993;30:779-782
54. Veltman JA, Jonkers Y, Nuijten I, et al. Definition of a critical region on chromosome 18 for congenital aural atresia by array CGH. Am J Hum Genet. 2003;72:1578-1584
55. Kline AD, White ME, Wapner R, et al. Molecular analysis of the 18q- syndrome and correlation with phenotype. Am J Hum Genet. 1993;52:895-906
56. Dostal A, Nemeckova J, Gaillyova R, et al. Identification of 2.3-Mb gene locus for congenital aural atresia in 18q22.3 deletion: a case report analysed by comparative genomic hybridisation. Otol Neurotol. 2003;27:427-432
57. Amiel J, Faivre L, Marianowskl R, Bonnet D, et al. Hypertelorism-microtia-clefting syndrome (Bixler syndrome): report of two unrelated cases. Clin Dysmorphol. 2001;10:15-18
58. Verloes A. Hypertelorism-microtia-clefting (HMC) syndrome. Gen Couns. 1994;5:283-287
59. Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med. 1985;313:837-841
60. Østensen M, Khamashata M, Lockshin M, et al. Antiinflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 2006;8:209